Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
Saved in:
| Title: | Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. |
|---|---|
| Authors: | McMichael A; Wake Forest University School of Medicine, Winston-Salem, North Carolina., Shahriari M; Yale University School of Medicine, New Haven, Connecticut.; Central Connecticut Dermatology, Cromwell., Stein Gold L; Henry Ford Health System, West Bloomfield, Michigan., Alkousakis T; Johnson & Johnson, Horsham, Pennsylvania., Choi O; Johnson & Johnson, Horsham, Pennsylvania., Bhutani T; Synergy Dermatology, San Francisco, California., Rodriguez AO; Nashville Skin Comprehensive Dermatology Center, Nashville, Tennessee., Tyring SK; Center for Clinical Studies, Webster, Texas.; University of Texas Health Science Center, Houston., Chan D; Johnson & Johnson, Horsham, Pennsylvania., Rowland K; Johnson & Johnson, Horsham, Pennsylvania., Albrecht L; Enverus Medical Research, Surrey, British Columbia, Canada.; University of British Columbia, Vancouver, British Columbia, Canada., Lynde C; The Lynde Institute for Dermatology & Lynderm Research Inc, Markham, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Yadav G; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; FACET Dermatology, Toronto, Ontario, Canada., Yeung J; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Park-Wyllie L; Johnson & Johnson, Toronto, Ontario, Canada., Ma T; Johnson & Johnson, Spring House, Pennsylvania., Jeyarajah J; Johnson & Johnson, Spring House, Pennsylvania., Gao LL; Johnson & Johnson, Spring House, Pennsylvania., Smith S; California Dermatology & Clinical Research Institute, Encinitas., Moore AY; Baylor University Medical Center, Dallas, Texas.; Arlington Research Center, Arlington, Texas., Vashi N; Boston University School of Medicine, Boston, Massachusetts., Kindred C; Kindred Hair & Skin Center, Marriottsville, Maryland.; Howard University College of Medicine, Washington, DC., Grimes P; The Grimes Center for Medical and Aesthetic Dermatology, Vitiligo and Pigmentation Institute of Southern California, Los Angeles., Desai SR; Innovative Dermatology, Plano, Texas.; University of Texas Southwestern Medical Center, Dallas., Taylor SC; University of Pennsylvania, Philadelphia., Alexis A; Weill Cornell Medicine, New York, New York. |
| Corporate Authors: | VISIBLE Trial Investigators |
| Source: | JAMA dermatology [JAMA Dermatol] 2025 Sep 01; Vol. 161 (9), pp. 912-922. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2025.1849 |
